Spring Bank Pharmaceuticals to Present at the East Coast IDEAS Investor Conference on May 18th in Boston
May 01 2017 - 08:00AM
Spring Bank Pharmaceuticals (NASDAQ:SBPH) today announced that
Martin Driscoll, president and chief executive officer of Spring
Bank Pharmaceuticals, will present at the East Coast IDEAS Investor
Conference on May 18, 2017 at the Boston Park Plaza in Boston,
Massachusetts. Spring Bank’s presentation is scheduled to begin at
10:00 a.m. EDT. The presentation will be webcast live and may be
accessed at the conference website, www.IDEASConferences.com, or on
the “Investors & Media” page of the company's website:
http://www.springbankpharm.com. The webcast will also be
archived on the “Investors & Media” page of the company’s
website.
About IDEAS Investor Conferences
The mission of the IDEAS Conferences is to
provide independent regional venues for quality companies to
present their investment merits to an influential audience of
investment professionals. Unlike traditional bank-sponsored
events, IDEAS Investor Conferences are “Sponsored BY the
Buyside FOR the Buyside” and for the benefit of regional
investment communities. Conference sponsors collectively have
more than $200 billion in assets under management and include:
Adirondack Research and Management, Allianz Global Investors: NFJ
Investment Group, Ariel Investments, Aristotle Capital Boston,
Barrow Hanley Mewhinney & Strauss, BMO Global Asset Management,
Constitution Research & Management, Inc., Fidelity Investments,
First Wilshire Securities Management, Inc., Gamco Investors,
Granahan Investment Management, Great Lakes Advisors, Greenbrier
Partners Capital Management, LLC, GRT Capital Partners, LLC, Hodges
Capital Management, Ironwood Investment Management, Keeley Asset
Management, Luther King Capital Management, Marble Harbor
Investment Counsel, Perritt Capital Management, Punch &
Associates, Westwood Holdings Group, Inc., and William Harris
Investors.
The IDEAS Investor Conferences are held annually
in Boston, Chicago and Dallas and are produced by Three Part
Advisors, LLC. Additional information about the events can be
located at www.IDEASconferences.com.
If interested in attending or learning more
about the IDEAS conferences, please contact Joe Noyons, (817)
778-8424, jnoyons@threepa.com.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage
biopharmaceutical company engaged in the discovery and development
of a novel class of therapeutics using its proprietary small
molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH
compounds are small segments of nucleic acids that the company
designs to selectively target and modulate the activity of specific
proteins implicated in various disease states. The company is
developing its most advanced SMNH product candidate, SB 9200, for
the treatment of viral diseases, including hepatitis B virus. SB
9200 has been designed to selectively activate within infected
cells the cellular proteins, retinoic acid-inducible gene 1, or
RIG-I, and nucleotide-binding oligomerization domain-containing
protein 2, or NOD2, which have been implicated in the body's immune
response to viral infections. Spring Bank believes that SB 9200 may
play an important role in antiviral therapy by modulating the
body's immune response through its mechanisms of action to fight
viral infections such as HBV. For more information, please visit:
http://www.springbankpharm.com.
Contact:
Jonathan Freve
Chief Financial Officer
(508) 500-4956
jfreve@springbankpharm.com
Spring Bank Pharmaceutic... (NASDAQ:SBPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Spring Bank Pharmaceutic... (NASDAQ:SBPH)
Historical Stock Chart
From Mar 2023 to Mar 2024